0
U.S. (TOLL FREE)
+1 (315) 215-3225
Automative

0
U.S. (TOLL FREE)
+1 (315) 215-3225
Global Meningococcal Disease Vaccine Market Research Report 2024
Published Date: July 2024
|
Report Code: QYRE-Auto-37Q13661
Home | Market Reports | Health| Health Conditions| Infectious Diseases
Global Meningococcal Disease Vaccine Market Research Report 2023
BUY CHAPTERS

Global Meningococcal Disease Vaccine Market Research Report 2024

Code: QYRE-Auto-37Q13661
Report
July 2024
Pages:89
QYResearch
Buy Now with 15% Discount
DESCRIPTION
TABLE OF CONTENT
TABLES & FIGURES

Meningococcal Disease Vaccine Market Size

The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years.

Meningococcal Disease Vaccine Market

Meningococcal Disease Vaccine Market

Meningococcal disease vaccination is a biological material given to prevent meningitis, a contagious disease of the membranes surrounding the spinal cord and brain. Conjugate, polysaccharide, and subcapsular meningococcal vaccines are the three main types of meningococcal vaccinations. They target meningococcal bacteria A, B, C, W-135, and Y and are given to new-borns, children, and adults to immunize them against the invasive disease. Antibodies are generated after the vaccination is given to combat the bacteria and develop an immune response to prevent infection.
The global Meningococcal Disease Vaccine market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % during the forecast period 2024-2030.
The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
This report aims to provide a comprehensive presentation of the global market for Meningococcal Disease Vaccine, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Meningococcal Disease Vaccine.

Report Scope

The Meningococcal Disease Vaccine market size, estimations, and forecasts are provided in terms of sales volume (K Units) and revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Meningococcal Disease Vaccine market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Meningococcal Disease Vaccine manufacturers, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation

Scope of Meningococcal Disease Vaccine Market Report

Report Metric Details
Report Name Meningococcal Disease Vaccine Market
CAGR 5%
Segment by Type
  • Polysaccharide
  • Conjugate
  • Combination
Segment by Application
  • Infant
  • Child
  • Aldult
Consumption by Region
  • North America (United States, Canada)
  • Europe (Germany, France, UK, Italy, Russia)
  • Asia-Pacific (China, Japan, South Korea, Taiwan)
  • Southeast Asia (India)
  • Latin America (Mexico, Brazil)
By Company AstraZeneca, Johnson & Johnson, Mylan N.V, Teva Pharmaceutical Industries Ltd, Pfizer Inc, GlaxoSmithKline plc, Novartis AG, Sanofi, Merck & Co., Inc., F. Hoffmann-La Roche Ltd, Baxter, BIO-MED, Bio-Manguinhos, Walvax Biotechnology Co., Ltd
Forecast units USD million in value
Report coverage Revenue and volume forecast, company share, competitive landscape, growth factors and trends

Chapter Outline

  • Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by region, by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
  • Chapter 2: Detailed analysis of Meningococcal Disease Vaccine manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
  • Chapter 3: Sales, revenue of Meningococcal Disease Vaccine in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and market size of each country in the world.
  • Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
  • Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
  • Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
  • Chapter 7: Analysis of industrial chain, including the upstream and downstream of the industry.
  • Chapter 8: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
  • Chapter 9: The main points and conclusions of the report.

FAQ for this report

Who are the main players in the Meningococcal Disease Vaccine Market report?

Ans: The main players in the Meningococcal Disease Vaccine Market are AstraZeneca, Johnson & Johnson, Mylan N.V, Teva Pharmaceutical Industries Ltd, Pfizer Inc, GlaxoSmithKline plc, Novartis AG, Sanofi, Merck & Co., Inc., F. Hoffmann-La Roche Ltd, Baxter, BIO-MED, Bio-Manguinhos, Walvax Biotechnology Co., Ltd

What are the Application segmentation covered in the Meningococcal Disease Vaccine Market report?

Ans: The Applications covered in the Meningococcal Disease Vaccine Market report are Infant, Child, Aldult

What are the Type segmentation covered in the Meningococcal Disease Vaccine Market report?

Ans: The Types covered in the Meningococcal Disease Vaccine Market report are Polysaccharide, Conjugate, Combination

1 Meningococcal Disease Vaccine Market Overview
1.1 Product Overview and Scope of Meningococcal Disease Vaccine
1.2 Meningococcal Disease Vaccine Segment by Type
1.2.1 Global Meningococcal Disease Vaccine Market Value Comparison by Type (2024-2030)
1.2.2 Polysaccharide
1.2.3 Conjugate
1.2.4 Combination
1.3 Meningococcal Disease Vaccine Segment by Application
1.3.1 Global Meningococcal Disease Vaccine Market Value by Application: (2024-2030)
1.3.2 Infant
1.3.3 Child
1.3.4 Aldult
1.4 Global Meningococcal Disease Vaccine Market Size Estimates and Forecasts
1.4.1 Global Meningococcal Disease Vaccine Revenue 2019-2030
1.4.2 Global Meningococcal Disease Vaccine Sales 2019-2030
1.4.3 Global Meningococcal Disease Vaccine Market Average Price (2019-2030)
1.5 Assumptions and Limitations
2 Meningococcal Disease Vaccine Market Competition by Manufacturers
2.1 Global Meningococcal Disease Vaccine Sales Market Share by Manufacturers (2019-2024)
2.2 Global Meningococcal Disease Vaccine Revenue Market Share by Manufacturers (2019-2024)
2.3 Global Meningococcal Disease Vaccine Average Price by Manufacturers (2019-2024)
2.4 Global Meningococcal Disease Vaccine Industry Ranking 2022 VS 2023 VS 2024
2.5 Global Key Manufacturers of Meningococcal Disease Vaccine, Manufacturing Sites & Headquarters
2.6 Global Key Manufacturers of Meningococcal Disease Vaccine, Product Type & Application
2.7 Meningococcal Disease Vaccine Market Competitive Situation and Trends
2.7.1 Meningococcal Disease Vaccine Market Concentration Rate
2.7.2 The Global Top 5 and Top 10 Largest Meningococcal Disease Vaccine Players Market Share by Revenue
2.7.3 Global Meningococcal Disease Vaccine Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
2.8 Manufacturers Mergers & Acquisitions, Expansion Plans
3 Meningococcal Disease Vaccine Retrospective Market Scenario by Region
3.1 Global Meningococcal Disease Vaccine Market Size by Region: 2019 Versus 2023 Versus 2030
3.2 Global Meningococcal Disease Vaccine Global Meningococcal Disease Vaccine Sales by Region: 2019-2030
3.2.1 Global Meningococcal Disease Vaccine Sales by Region: 2019-2024
3.2.2 Global Meningococcal Disease Vaccine Sales by Region: 2025-2030
3.3 Global Meningococcal Disease Vaccine Global Meningococcal Disease Vaccine Revenue by Region: 2019-2030
3.3.1 Global Meningococcal Disease Vaccine Revenue by Region: 2019-2024
3.3.2 Global Meningococcal Disease Vaccine Revenue by Region: 2025-2030
3.4 North America Meningococcal Disease Vaccine Market Facts & Figures by Country
3.4.1 North America Meningococcal Disease Vaccine Market Size by Country: 2019 VS 2023 VS 2030
3.4.2 North America Meningococcal Disease Vaccine Sales by Country (2019-2030)
3.4.3 North America Meningococcal Disease Vaccine Revenue by Country (2019-2030)
3.4.4 United States
3.4.5 Canada
3.5 Europe Meningococcal Disease Vaccine Market Facts & Figures by Country
3.5.1 Europe Meningococcal Disease Vaccine Market Size by Country: 2019 VS 2023 VS 2030
3.5.2 Europe Meningococcal Disease Vaccine Sales by Country (2019-2030)
3.5.3 Europe Meningococcal Disease Vaccine Revenue by Country (2019-2030)
3.5.4 Germany
3.5.5 France
3.5.6 U.K.
3.5.7 Italy
3.5.8 Russia
3.6 Asia Pacific Meningococcal Disease Vaccine Market Facts & Figures by Country
3.6.1 Asia Pacific Meningococcal Disease Vaccine Market Size by Country: 2019 VS 2023 VS 2030
3.6.2 Asia Pacific Meningococcal Disease Vaccine Sales by Country (2019-2030)
3.6.3 Asia Pacific Meningococcal Disease Vaccine Revenue by Country (2019-2030)
3.6.4 China
3.6.5 Japan
3.6.6 South Korea
3.6.7 India
3.6.8 Australia
3.6.9 China Taiwan
3.6.10 Southeast Asia
3.7 Latin America Meningococcal Disease Vaccine Market Facts & Figures by Country
3.7.1 Latin America Meningococcal Disease Vaccine Market Size by Country: 2019 VS 2023 VS 2030
3.7.2 Latin America Meningococcal Disease Vaccine Sales by Country (2019-2030)
3.7.3 Latin America Meningococcal Disease Vaccine Revenue by Country (2019-2030)
3.7.4 Mexico
3.7.5 Brazil
3.7.6 Argentina
3.8 Middle East and Africa Meningococcal Disease Vaccine Market Facts & Figures by Country
3.8.1 Middle East and Africa Meningococcal Disease Vaccine Market Size by Country: 2019 VS 2023 VS 2030
3.8.2 Middle East and Africa Meningococcal Disease Vaccine Sales by Country (2019-2030)
3.8.3 Middle East and Africa Meningococcal Disease Vaccine Revenue by Country (2019-2030)
3.8.4 Turkey
3.8.5 Saudi Arabia
3.8.6 UAE
4 Segment by Type
4.1 Global Meningococcal Disease Vaccine Sales by Type (2019-2030)
4.1.1 Global Meningococcal Disease Vaccine Sales by Type (2019-2024)
4.1.2 Global Meningococcal Disease Vaccine Sales by Type (2025-2030)
4.1.3 Global Meningococcal Disease Vaccine Sales Market Share by Type (2019-2030)
4.2 Global Meningococcal Disease Vaccine Revenue by Type (2019-2030)
4.2.1 Global Meningococcal Disease Vaccine Revenue by Type (2019-2024)
4.2.2 Global Meningococcal Disease Vaccine Revenue by Type (2025-2030)
4.2.3 Global Meningococcal Disease Vaccine Revenue Market Share by Type (2019-2030)
4.3 Global Meningococcal Disease Vaccine Price by Type (2019-2030)
5 Segment by Application
5.1 Global Meningococcal Disease Vaccine Sales by Application (2019-2030)
5.1.1 Global Meningococcal Disease Vaccine Sales by Application (2019-2024)
5.1.2 Global Meningococcal Disease Vaccine Sales by Application (2025-2030)
5.1.3 Global Meningococcal Disease Vaccine Sales Market Share by Application (2019-2030)
5.2 Global Meningococcal Disease Vaccine Revenue by Application (2019-2030)
5.2.1 Global Meningococcal Disease Vaccine Revenue by Application (2019-2024)
5.2.2 Global Meningococcal Disease Vaccine Revenue by Application (2025-2030)
5.2.3 Global Meningococcal Disease Vaccine Revenue Market Share by Application (2019-2030)
5.3 Global Meningococcal Disease Vaccine Price by Application (2019-2030)
6 Key Companies Profiled
6.1 AstraZeneca
6.1.1 AstraZeneca Corporation Information
6.1.2 AstraZeneca Description and Business Overview
6.1.3 AstraZeneca Meningococcal Disease Vaccine Sales, Revenue and Gross Margin (2019-2024)
6.1.4 AstraZeneca Meningococcal Disease Vaccine Product Portfolio
6.1.5 AstraZeneca Recent Developments/Updates
6.2 Johnson & Johnson
6.2.1 Johnson & Johnson Corporation Information
6.2.2 Johnson & Johnson Description and Business Overview
6.2.3 Johnson & Johnson Meningococcal Disease Vaccine Sales, Revenue and Gross Margin (2019-2024)
6.2.4 Johnson & Johnson Meningococcal Disease Vaccine Product Portfolio
6.2.5 Johnson & Johnson Recent Developments/Updates
6.3 Mylan N.V
6.3.1 Mylan N.V Corporation Information
6.3.2 Mylan N.V Description and Business Overview
6.3.3 Mylan N.V Meningococcal Disease Vaccine Sales, Revenue and Gross Margin (2019-2024)
6.3.4 Mylan N.V Meningococcal Disease Vaccine Product Portfolio
6.3.5 Mylan N.V Recent Developments/Updates
6.4 Teva Pharmaceutical Industries Ltd
6.4.1 Teva Pharmaceutical Industries Ltd Corporation Information
6.4.2 Teva Pharmaceutical Industries Ltd Description and Business Overview
6.4.3 Teva Pharmaceutical Industries Ltd Meningococcal Disease Vaccine Sales, Revenue and Gross Margin (2019-2024)
6.4.4 Teva Pharmaceutical Industries Ltd Meningococcal Disease Vaccine Product Portfolio
6.4.5 Teva Pharmaceutical Industries Ltd Recent Developments/Updates
6.5 Pfizer Inc
6.5.1 Pfizer Inc Corporation Information
6.5.2 Pfizer Inc Description and Business Overview
6.5.3 Pfizer Inc Meningococcal Disease Vaccine Sales, Revenue and Gross Margin (2019-2024)
6.5.4 Pfizer Inc Meningococcal Disease Vaccine Product Portfolio
6.5.5 Pfizer Inc Recent Developments/Updates
6.6 GlaxoSmithKline plc
6.6.1 GlaxoSmithKline plc Corporation Information
6.6.2 GlaxoSmithKline plc Description and Business Overview
6.6.3 GlaxoSmithKline plc Meningococcal Disease Vaccine Sales, Revenue and Gross Margin (2019-2024)
6.6.4 GlaxoSmithKline plc Meningococcal Disease Vaccine Product Portfolio
6.6.5 GlaxoSmithKline plc Recent Developments/Updates
6.7 Novartis AG
6.6.1 Novartis AG Corporation Information
6.6.2 Novartis AG Description and Business Overview
6.6.3 Novartis AG Meningococcal Disease Vaccine Sales, Revenue and Gross Margin (2019-2024)
6.4.4 Novartis AG Meningococcal Disease Vaccine Product Portfolio
6.7.5 Novartis AG Recent Developments/Updates
6.8 Sanofi
6.8.1 Sanofi Corporation Information
6.8.2 Sanofi Description and Business Overview
6.8.3 Sanofi Meningococcal Disease Vaccine Sales, Revenue and Gross Margin (2019-2024)
6.8.4 Sanofi Meningococcal Disease Vaccine Product Portfolio
6.8.5 Sanofi Recent Developments/Updates
6.9 Merck & Co., Inc.
6.9.1 Merck & Co., Inc. Corporation Information
6.9.2 Merck & Co., Inc. Description and Business Overview
6.9.3 Merck & Co., Inc. Meningococcal Disease Vaccine Sales, Revenue and Gross Margin (2019-2024)
6.9.4 Merck & Co., Inc. Meningococcal Disease Vaccine Product Portfolio
6.9.5 Merck & Co., Inc. Recent Developments/Updates
6.10 F. Hoffmann-La Roche Ltd
6.10.1 F. Hoffmann-La Roche Ltd Corporation Information
6.10.2 F. Hoffmann-La Roche Ltd Description and Business Overview
6.10.3 F. Hoffmann-La Roche Ltd Meningococcal Disease Vaccine Sales, Revenue and Gross Margin (2019-2024)
6.10.4 F. Hoffmann-La Roche Ltd Meningococcal Disease Vaccine Product Portfolio
6.10.5 F. Hoffmann-La Roche Ltd Recent Developments/Updates
6.11 Baxter
6.11.1 Baxter Corporation Information
6.11.2 Baxter Meningococcal Disease Vaccine Description and Business Overview
6.11.3 Baxter Meningococcal Disease Vaccine Sales, Revenue and Gross Margin (2019-2024)
6.11.4 Baxter Meningococcal Disease Vaccine Product Portfolio
6.11.5 Baxter Recent Developments/Updates
6.12 BIO-MED
6.12.1 BIO-MED Corporation Information
6.12.2 BIO-MED Meningococcal Disease Vaccine Description and Business Overview
6.12.3 BIO-MED Meningococcal Disease Vaccine Sales, Revenue and Gross Margin (2019-2024)
6.12.4 BIO-MED Meningococcal Disease Vaccine Product Portfolio
6.12.5 BIO-MED Recent Developments/Updates
6.13 Bio-Manguinhos
6.13.1 Bio-Manguinhos Corporation Information
6.13.2 Bio-Manguinhos Meningococcal Disease Vaccine Description and Business Overview
6.13.3 Bio-Manguinhos Meningococcal Disease Vaccine Sales, Revenue and Gross Margin (2019-2024)
6.13.4 Bio-Manguinhos Meningococcal Disease Vaccine Product Portfolio
6.13.5 Bio-Manguinhos Recent Developments/Updates
6.14 Walvax Biotechnology Co., Ltd
6.14.1 Walvax Biotechnology Co., Ltd Corporation Information
6.14.2 Walvax Biotechnology Co., Ltd Meningococcal Disease Vaccine Description and Business Overview
6.14.3 Walvax Biotechnology Co., Ltd Meningococcal Disease Vaccine Sales, Revenue and Gross Margin (2019-2024)
6.14.4 Walvax Biotechnology Co., Ltd Meningococcal Disease Vaccine Product Portfolio
6.14.5 Walvax Biotechnology Co., Ltd Recent Developments/Updates
7 Industry Chain and Sales Channels Analysis
7.1 Meningococcal Disease Vaccine Industry Chain Analysis
7.2 Meningococcal Disease Vaccine Key Raw Materials
7.2.1 Key Raw Materials
7.2.2 Raw Materials Key Suppliers
7.3 Meningococcal Disease Vaccine Production Mode & Process
7.4 Meningococcal Disease Vaccine Sales and Marketing
7.4.1 Meningococcal Disease Vaccine Sales Channels
7.4.2 Meningococcal Disease Vaccine Distributors
7.5 Meningococcal Disease Vaccine Customers
8 Meningococcal Disease Vaccine Market Dynamics
8.1 Meningococcal Disease Vaccine Industry Trends
8.2 Meningococcal Disease Vaccine Market Drivers
8.3 Meningococcal Disease Vaccine Market Challenges
8.4 Meningococcal Disease Vaccine Market Restraints
9 Research Finding and Conclusion
10 Methodology and Data Source
10.1 Methodology/Research Approach
10.1.1 Research Programs/Design
10.1.2 Market Size Estimation
10.1.3 Market Breakdown and Data Triangulation
10.2 Data Source
10.2.1 Secondary Sources
10.2.2 Primary Sources
10.3 Author List
10.4 Disclaimer
List of Tables
    Table 1. Global Meningococcal Disease Vaccine Market Value Comparison by Type (2024-2030) & (US$ Million)
    Table 2. Global Meningococcal Disease Vaccine Market Value Comparison by Application (2024-2030) & (US$ Million)
    Table 3. Global Meningococcal Disease Vaccine Market Competitive Situation by Manufacturers in 2023
    Table 4. Global Meningococcal Disease Vaccine Sales (K Units) of Key Manufacturers (2019-2024)
    Table 5. Global Meningococcal Disease Vaccine Sales Market Share by Manufacturers (2019-2024)
    Table 6. Global Meningococcal Disease Vaccine Revenue (US$ Million) by Manufacturers (2019-2024)
    Table 7. Global Meningococcal Disease Vaccine Revenue Share by Manufacturers (2019-2024)
    Table 8. Global Market Meningococcal Disease Vaccine Average Price (US$/Unit) of Key Manufacturers (2019-2024)
    Table 9. Global Key Players of Meningococcal Disease Vaccine, Industry Ranking, 2022 VS 2023 VS 2024
    Table 10. Global Key Manufacturers of Meningococcal Disease Vaccine, Manufacturing Sites & Headquarters
    Table 11. Global Key Manufacturers of Meningococcal Disease Vaccine, Product Type & Application
    Table 12. Global Key Manufacturers of Meningococcal Disease Vaccine, Date of Enter into This Industry
    Table 13. Global Manufacturers Market Concentration Ratio (CR5 and HHI)
    Table 14. Global Meningococcal Disease Vaccine by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Meningococcal Disease Vaccine as of 2023)
    Table 15. Manufacturers Mergers & Acquisitions, Expansion Plans
    Table 16. Global Meningococcal Disease Vaccine Market Size by Region (US$ Million): 2019 VS 2023 VS 2030
    Table 17. Global Meningococcal Disease Vaccine Sales by Region (2019-2024) & (K Units)
    Table 18. Global Meningococcal Disease Vaccine Sales Market Share by Region (2019-2024)
    Table 19. Global Meningococcal Disease Vaccine Sales by Region (2025-2030) & (K Units)
    Table 20. Global Meningococcal Disease Vaccine Sales Market Share by Region (2025-2030)
    Table 21. Global Meningococcal Disease Vaccine Revenue by Region (2019-2024) & (US$ Million)
    Table 22. Global Meningococcal Disease Vaccine Revenue Market Share by Region (2019-2024)
    Table 23. Global Meningococcal Disease Vaccine Revenue by Region (2025-2030) & (US$ Million)
    Table 24. Global Meningococcal Disease Vaccine Revenue Market Share by Region (2025-2030)
    Table 25. North America Meningococcal Disease Vaccine Revenue by Country: 2019 VS 2023 VS 2030 (US$ Million)
    Table 26. North America Meningococcal Disease Vaccine Sales by Country (2019-2024) & (K Units)
    Table 27. North America Meningococcal Disease Vaccine Sales by Country (2025-2030) & (K Units)
    Table 28. North America Meningococcal Disease Vaccine Revenue by Country (2019-2024) & (US$ Million)
    Table 29. North America Meningococcal Disease Vaccine Revenue by Country (2025-2030) & (US$ Million)
    Table 30. Europe Meningococcal Disease Vaccine Revenue by Country: 2019 VS 2023 VS 2030 (US$ Million)
    Table 31. Europe Meningococcal Disease Vaccine Sales by Country (2019-2024) & (K Units)
    Table 32. Europe Meningococcal Disease Vaccine Sales by Country (2025-2030) & (K Units)
    Table 33. Europe Meningococcal Disease Vaccine Revenue by Country (2019-2024) & (US$ Million)
    Table 34. Europe Meningococcal Disease Vaccine Revenue by Country (2025-2030) & (US$ Million)
    Table 35. Asia Pacific Meningococcal Disease Vaccine Revenue by Region: 2019 VS 2023 VS 2030 (US$ Million)
    Table 36. Asia Pacific Meningococcal Disease Vaccine Sales by Region (2019-2024) & (K Units)
    Table 37. Asia Pacific Meningococcal Disease Vaccine Sales by Region (2025-2030) & (K Units)
    Table 38. Asia Pacific Meningococcal Disease Vaccine Revenue by Region (2019-2024) & (US$ Million)
    Table 39. Asia Pacific Meningococcal Disease Vaccine Revenue by Region (2025-2030) & (US$ Million)
    Table 40. Latin America Meningococcal Disease Vaccine Revenue by Country: 2019 VS 2023 VS 2030 (US$ Million)
    Table 41. Latin America Meningococcal Disease Vaccine Sales by Country (2019-2024) & (K Units)
    Table 42. Latin America Meningococcal Disease Vaccine Sales by Country (2025-2030) & (K Units)
    Table 43. Latin America Meningococcal Disease Vaccine Revenue by Country (2019-2024) & (US$ Million)
    Table 44. Latin America Meningococcal Disease Vaccine Revenue by Country (2025-2030) & (US$ Million)
    Table 45. Middle East & Africa Meningococcal Disease Vaccine Revenue by Country: 2019 VS 2023 VS 2030 (US$ Million)
    Table 46. Middle East & Africa Meningococcal Disease Vaccine Sales by Country (2019-2024) & (K Units)
    Table 47. Middle East & Africa Meningococcal Disease Vaccine Sales by Country (2025-2030) & (K Units)
    Table 48. Middle East & Africa Meningococcal Disease Vaccine Revenue by Country (2019-2024) & (US$ Million)
    Table 49. Middle East & Africa Meningococcal Disease Vaccine Revenue by Country (2025-2030) & (US$ Million)
    Table 50. Global Meningococcal Disease Vaccine Sales (K Units) by Type (2019-2024)
    Table 51. Global Meningococcal Disease Vaccine Sales (K Units) by Type (2025-2030)
    Table 52. Global Meningococcal Disease Vaccine Sales Market Share by Type (2019-2024)
    Table 53. Global Meningococcal Disease Vaccine Sales Market Share by Type (2025-2030)
    Table 54. Global Meningococcal Disease Vaccine Revenue (US$ Million) by Type (2019-2024)
    Table 55. Global Meningococcal Disease Vaccine Revenue (US$ Million) by Type (2025-2030)
    Table 56. Global Meningococcal Disease Vaccine Revenue Market Share by Type (2019-2024)
    Table 57. Global Meningococcal Disease Vaccine Revenue Market Share by Type (2025-2030)
    Table 58. Global Meningococcal Disease Vaccine Price (US$/Unit) by Type (2019-2024)
    Table 59. Global Meningococcal Disease Vaccine Price (US$/Unit) by Type (2025-2030)
    Table 60. Global Meningococcal Disease Vaccine Sales (K Units) by Application (2019-2024)
    Table 61. Global Meningococcal Disease Vaccine Sales (K Units) by Application (2025-2030)
    Table 62. Global Meningococcal Disease Vaccine Sales Market Share by Application (2019-2024)
    Table 63. Global Meningococcal Disease Vaccine Sales Market Share by Application (2025-2030)
    Table 64. Global Meningococcal Disease Vaccine Revenue (US$ Million) by Application (2019-2024)
    Table 65. Global Meningococcal Disease Vaccine Revenue (US$ Million) by Application (2025-2030)
    Table 66. Global Meningococcal Disease Vaccine Revenue Market Share by Application (2019-2024)
    Table 67. Global Meningococcal Disease Vaccine Revenue Market Share by Application (2025-2030)
    Table 68. Global Meningococcal Disease Vaccine Price (US$/Unit) by Application (2019-2024)
    Table 69. Global Meningococcal Disease Vaccine Price (US$/Unit) by Application (2025-2030)
    Table 70. AstraZeneca Corporation Information
    Table 71. AstraZeneca Description and Business Overview
    Table 72. AstraZeneca Meningococcal Disease Vaccine Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
    Table 73. AstraZeneca Meningococcal Disease Vaccine Product
    Table 74. AstraZeneca Recent Developments/Updates
    Table 75. Johnson & Johnson Corporation Information
    Table 76. Johnson & Johnson Description and Business Overview
    Table 77. Johnson & Johnson Meningococcal Disease Vaccine Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
    Table 78. Johnson & Johnson Meningococcal Disease Vaccine Product
    Table 79. Johnson & Johnson Recent Developments/Updates
    Table 80. Mylan N.V Corporation Information
    Table 81. Mylan N.V Description and Business Overview
    Table 82. Mylan N.V Meningococcal Disease Vaccine Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
    Table 83. Mylan N.V Meningococcal Disease Vaccine Product
    Table 84. Mylan N.V Recent Developments/Updates
    Table 85. Teva Pharmaceutical Industries Ltd Corporation Information
    Table 86. Teva Pharmaceutical Industries Ltd Description and Business Overview
    Table 87. Teva Pharmaceutical Industries Ltd Meningococcal Disease Vaccine Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
    Table 88. Teva Pharmaceutical Industries Ltd Meningococcal Disease Vaccine Product
    Table 89. Teva Pharmaceutical Industries Ltd Recent Developments/Updates
    Table 90. Pfizer Inc Corporation Information
    Table 91. Pfizer Inc Description and Business Overview
    Table 92. Pfizer Inc Meningococcal Disease Vaccine Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
    Table 93. Pfizer Inc Meningococcal Disease Vaccine Product
    Table 94. Pfizer Inc Recent Developments/Updates
    Table 95. GlaxoSmithKline plc Corporation Information
    Table 96. GlaxoSmithKline plc Description and Business Overview
    Table 97. GlaxoSmithKline plc Meningococcal Disease Vaccine Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
    Table 98. GlaxoSmithKline plc Meningococcal Disease Vaccine Product
    Table 99. GlaxoSmithKline plc Recent Developments/Updates
    Table 100. Novartis AG Corporation Information
    Table 101. Novartis AG Description and Business Overview
    Table 102. Novartis AG Meningococcal Disease Vaccine Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
    Table 103. Novartis AG Meningococcal Disease Vaccine Product
    Table 104. Novartis AG Recent Developments/Updates
    Table 105. Sanofi Corporation Information
    Table 106. Sanofi Description and Business Overview
    Table 107. Sanofi Meningococcal Disease Vaccine Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
    Table 108. Sanofi Meningococcal Disease Vaccine Product
    Table 109. Sanofi Recent Developments/Updates
    Table 110. Merck & Co., Inc. Corporation Information
    Table 111. Merck & Co., Inc. Description and Business Overview
    Table 112. Merck & Co., Inc. Meningococcal Disease Vaccine Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
    Table 113. Merck & Co., Inc. Meningococcal Disease Vaccine Product
    Table 114. Merck & Co., Inc. Recent Developments/Updates
    Table 115. F. Hoffmann-La Roche Ltd Corporation Information
    Table 116. F. Hoffmann-La Roche Ltd Description and Business Overview
    Table 117. F. Hoffmann-La Roche Ltd Meningococcal Disease Vaccine Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
    Table 118. F. Hoffmann-La Roche Ltd Meningococcal Disease Vaccine Product
    Table 119. F. Hoffmann-La Roche Ltd Recent Developments/Updates
    Table 120. Baxter Corporation Information
    Table 121. Baxter Description and Business Overview
    Table 122. Baxter Meningococcal Disease Vaccine Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
    Table 123. Baxter Meningococcal Disease Vaccine Product
    Table 124. Baxter Recent Developments/Updates
    Table 125. BIO-MED Corporation Information
    Table 126. BIO-MED Description and Business Overview
    Table 127. BIO-MED Meningococcal Disease Vaccine Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
    Table 128. BIO-MED Meningococcal Disease Vaccine Product
    Table 129. BIO-MED Recent Developments/Updates
    Table 130. Bio-Manguinhos Corporation Information
    Table 131. Bio-Manguinhos Description and Business Overview
    Table 132. Bio-Manguinhos Meningococcal Disease Vaccine Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
    Table 133. Bio-Manguinhos Meningococcal Disease Vaccine Product
    Table 134. Bio-Manguinhos Recent Developments/Updates
    Table 135. Walvax Biotechnology Co., Ltd Corporation Information
    Table 136. Walvax Biotechnology Co., Ltd Description and Business Overview
    Table 137. Walvax Biotechnology Co., Ltd Meningococcal Disease Vaccine Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
    Table 138. Walvax Biotechnology Co., Ltd Meningococcal Disease Vaccine Product
    Table 139. Walvax Biotechnology Co., Ltd Recent Developments/Updates
    Table 140. Key Raw Materials Lists
    Table 141. Raw Materials Key Suppliers Lists
    Table 142. Meningococcal Disease Vaccine Distributors List
    Table 143. Meningococcal Disease Vaccine Customers List
    Table 144. Meningococcal Disease Vaccine Market Trends
    Table 145. Meningococcal Disease Vaccine Market Drivers
    Table 146. Meningococcal Disease Vaccine Market Challenges
    Table 147. Meningococcal Disease Vaccine Market Restraints
    Table 148. Research Programs/Design for This Report
    Table 149. Key Data Information from Secondary Sources
    Table 150. Key Data Information from Primary Sources
List of Figures
    Figure 1. Product Picture of Meningococcal Disease Vaccine
    Figure 2. Global Meningococcal Disease Vaccine Market Value Comparison by Type (2024-2030) & (US$ Million)
    Figure 3. Global Meningococcal Disease Vaccine Market Share by Type in 2023 & 2030
    Figure 4. Polysaccharide Product Picture
    Figure 5. Conjugate Product Picture
    Figure 6. Combination Product Picture
    Figure 7. Global Meningococcal Disease Vaccine Market Value Comparison by Application (2024-2030) & (US$ Million)
    Figure 8. Global Meningococcal Disease Vaccine Market Share by Application in 2023 & 2030
    Figure 9. Infant
    Figure 10. Child
    Figure 11. Aldult
    Figure 12. Global Meningococcal Disease Vaccine Revenue, (US$ Million), 2019 VS 2023 VS 2030
    Figure 13. Global Meningococcal Disease Vaccine Market Size (2019-2030) & (US$ Million)
    Figure 14. Global Meningococcal Disease Vaccine Sales (2019-2030) & (K Units)
    Figure 15. Global Meningococcal Disease Vaccine Average Price (US$/Unit) & (2019-2030)
    Figure 16. Meningococcal Disease Vaccine Report Years Considered
    Figure 17. Meningococcal Disease Vaccine Sales Share by Manufacturers in 2023
    Figure 18. Global Meningococcal Disease Vaccine Revenue Share by Manufacturers in 2023
    Figure 19. The Global 5 and 10 Largest Meningococcal Disease Vaccine Players: Market Share by Revenue in 2023
    Figure 20. Meningococcal Disease Vaccine Market Share by Company Type (Tier 1, Tier 2 and Tier 3): 2019 VS 2023
    Figure 21. Global Meningococcal Disease Vaccine Market Size by Region (US$ Million): 2019 VS 2023 VS 2030
    Figure 22. North America Meningococcal Disease Vaccine Sales Market Share by Country (2019-2030)
    Figure 23. North America Meningococcal Disease Vaccine Revenue Market Share by Country (2019-2030)
    Figure 24. United States Meningococcal Disease Vaccine Revenue Growth Rate (2019-2030) & (US$ Million)
    Figure 25. Canada Meningococcal Disease Vaccine Revenue Growth Rate (2019-2030) & (US$ Million)
    Figure 26. Europe Meningococcal Disease Vaccine Sales Market Share by Country (2019-2030)
    Figure 27. Europe Meningococcal Disease Vaccine Revenue Market Share by Country (2019-2030)
    Figure 28. Germany Meningococcal Disease Vaccine Revenue Growth Rate (2019-2030) & (US$ Million)
    Figure 29. France Meningococcal Disease Vaccine Revenue Growth Rate (2019-2030) & (US$ Million)
    Figure 30. U.K. Meningococcal Disease Vaccine Revenue Growth Rate (2019-2030) & (US$ Million)
    Figure 31. Italy Meningococcal Disease Vaccine Revenue Growth Rate (2019-2030) & (US$ Million)
    Figure 32. Russia Meningococcal Disease Vaccine Revenue Growth Rate (2019-2030) & (US$ Million)
    Figure 33. Asia Pacific Meningococcal Disease Vaccine Sales Market Share by Region (2019-2030)
    Figure 34. Asia Pacific Meningococcal Disease Vaccine Revenue Market Share by Region (2019-2030)
    Figure 35. China Meningococcal Disease Vaccine Revenue Growth Rate (2019-2030) & (US$ Million)
    Figure 36. Japan Meningococcal Disease Vaccine Revenue Growth Rate (2019-2030) & (US$ Million)
    Figure 37. South Korea Meningococcal Disease Vaccine Revenue Growth Rate (2019-2030) & (US$ Million)
    Figure 38. India Meningococcal Disease Vaccine Revenue Growth Rate (2019-2030) & (US$ Million)
    Figure 39. Australia Meningococcal Disease Vaccine Revenue Growth Rate (2019-2030) & (US$ Million)
    Figure 40. China Taiwan Meningococcal Disease Vaccine Revenue Growth Rate (2019-2030) & (US$ Million)
    Figure 41. Southeast Asia Meningococcal Disease Vaccine Revenue Growth Rate (2019-2030) & (US$ Million)
    Figure 42. Latin America Meningococcal Disease Vaccine Sales Market Share by Country (2019-2030)
    Figure 43. Latin America Meningococcal Disease Vaccine Revenue Market Share by Country (2019-2030)
    Figure 44. Mexico Meningococcal Disease Vaccine Revenue Growth Rate (2019-2030) & (US$ Million)
    Figure 45. Brazil Meningococcal Disease Vaccine Revenue Growth Rate (2019-2030) & (US$ Million)
    Figure 46. Argentina Meningococcal Disease Vaccine Revenue Growth Rate (2019-2030) & (US$ Million)
    Figure 47. Middle East & Africa Meningococcal Disease Vaccine Sales Market Share by Country (2019-2030)
    Figure 48. Middle East & Africa Meningococcal Disease Vaccine Revenue Market Share by Country (2019-2030)
    Figure 49. Turkey Meningococcal Disease Vaccine Revenue Growth Rate (2019-2030) & (US$ Million)
    Figure 50. Saudi Arabia Meningococcal Disease Vaccine Revenue Growth Rate (2019-2030) & (US$ Million)
    Figure 51. UAE Meningococcal Disease Vaccine Revenue Growth Rate (2019-2030) & (US$ Million)
    Figure 52. Global Sales Market Share of Meningococcal Disease Vaccine by Type (2019-2030)
    Figure 53. Global Revenue Market Share of Meningococcal Disease Vaccine by Type (2019-2030)
    Figure 54. Global Meningococcal Disease Vaccine Price (US$/Unit) by Type (2019-2030)
    Figure 55. Global Sales Market Share of Meningococcal Disease Vaccine by Application (2019-2030)
    Figure 56. Global Revenue Market Share of Meningococcal Disease Vaccine by Application (2019-2030)
    Figure 57. Global Meningococcal Disease Vaccine Price (US$/Unit) by Application (2019-2030)
    Figure 58. Meningococcal Disease Vaccine Value Chain
    Figure 59. Meningococcal Disease Vaccine Production Process
    Figure 60. Channels of Distribution (Direct Vs Distribution)
    Figure 61. Distributors Profiles
    Figure 62. Bottom-up and Top-down Approaches for This Report
    Figure 63. Data Triangulation
    Figure 64. Key Executives Interviewed
SELECT A FORMAT
Added to Cart
Electronic (PDF)

$2900

This license allows only one user to access the PDF.
Electronic (PDF)

$4350

This license allows 1 - 5 user to access the PDF, license is suitable for small groups of 5 users working together
Electronic (PDF)

$5800

This license allows users/teams in a same Enterprise to use this report, various departments within an enterpise can use this report
Add to Cart
Buy Now (15% Discount)

OUR CUSTOMER

Strategic Venue Partners

SIMILAR REPORTS